{"id":24488,"date":"2023-02-15T09:09:42","date_gmt":"2023-02-15T09:09:42","guid":{"rendered":"https:\/\/rhepa.se\/?page_id=24488"},"modified":"2026-02-11T14:39:15","modified_gmt":"2026-02-11T14:39:15","slug":"vetenskapligt-rad","status":"publish","type":"page","link":"https:\/\/rhepa.se\/en\/vetenskapligt-rad\/","title":{"rendered":"Scientific Advisory Board"},"content":{"rendered":"
\n\t\t\t\t
\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Scientific Advisory Board<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Our Scientific Advisory Board consists of eminent medical experts, professors and doctors with deep specialist knowledge within different medical fields. The board members each have their own broad global network of medical experts. In total, hundereds of experts and researchers at scientific institutions are included around the world in this extended network. This gives the portfolio managers opportunity to gain deeper insights and understanding, and to access the latest research. <\/p>\n

The work is led by its chair, Professor Sten Nilsson, with Henrik Rhenman as rapporteur.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Professor Sten Nilsson\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Chairman \/ Professor emeritus of Oncology\n\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Professor emeritus of Oncology and affiliated with Karolinska Institutet. Specialist in oncology and nuclear medicine. Former chairman of the Swedish Society of Oncology (SOF), the Swedish Society for Nuclear Medicine (SFNM) and the Swedish Society of Urological Oncology (SFUO). Sten has published more than 200 original papers in the scientific literature.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Professor Peter Arner\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Professor of Medicine\n\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Distinguished professor at Karolinska Institutet. Expert physician and scientist in metabolism and endocrinology. Started Lipid Laboratory at Karolinska Institutet performing research on metabolic diseases with focus on human adipose tissue. His current studies are on long-term effects of disturbed human fat cell function.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Professor Jan Lundberg\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Professor of Neurotransmission\n\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Previous professor of neurotransmission at the Pharmaceutical Faculty, Karolinska Institutet, and honorary doctor at the Pharmaceutical Faculty, Uppsala University, with more than 500 publications of scientific original articles. Recipient of the Fernstr\u00f6m and Jahre awards. Previous head of research for AstraZeneca and Global R&D president for Eli Lilly. Has been involved in bringing 25 new medicines to regulatory approval and patients including several blockbusters. Cofounder of Aerocrine AB and currently a board member of 6 different biotechnology companies.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Dr. Fredrik Swahn\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Doctor of Medicine\n\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

MD, PhD. Karolinska University Hospital Huddinge, Karolinska Comprehensive Cancer Center, Section for Upper GI. Dissertation at Karolinska Institute 2012. Board member in the scientific research group (ANDRE) within the Scandinavian Association for Digestive Endoscopy (SADE), previous chairman of the Endoscopy Committee of Swedish Association of Gastroenterology, faculty member of the European Society of Gastrointestinal Endoscopy (ESGE). For 23 years, clinically active as specialist in surgery, senior consultant with focus towards endoluminal surgery and also lecturing and organizing courses within the same topics.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Professor Tomas Olsson\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Professor of Neurology\n\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Professor of Neurology at Karolinska Institutet. Expert within the areas of auto-immune diseases and diseases of the nervous system. Has received several awards including the Fernstr\u00f6m Prize for young scientists. Has received a lifetime award for excellent MS research by the European Committee for the research and treatment of multiple sclerosis (ECTRIMS). Previously president for the International Society for Neuroimmunology (ISNI). Has published more than 600 articles, many of them in high impact journals. He now is a leader for a research group on neuro-immunological diseases at the center for molecular medicine, Karolinska Institutet.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Professor Ulf Eriksson\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Professor of Vascular Biochemistry\n\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Distinguished professor at Vetenskapsr\u00e5det (the Swedish Research Council) and at Karolinska Institutet. Expert in vascular biology, especially regarding the role of blood vessels in metabolism, diabetes and stroke. Member of the Nobel Committee at Karolinska Institutet and was its chairman in 2022. Ulf holds several faculty assignments at Karolinska Institutet and has received the Swedish Medical Society's Jubilee Award and The Svedbergs Award. He has also published more than 175 research articles, many in leading international journals.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Dr. G\u00f6ran Ando\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Doctor of Medicine\n\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

G\u00f6ran Ando is a medical doctor and has more than 40 years of leadership in the biotech and pharmaceutical industry, including 13 years as vice-chairman and chairman of Novo Nordisk AS. He joined the industry with Pfizer and has subsequently spent most time with Glaxo (now GSK) as medical director advancing to development director and finally R&D Director. In 1995 he joined Pharmacia as Executive Vice President and Deputy CEO heading R&D, manufacturing, IT, BD and M&A. When Pharmacia was sold in 2003, he was appointed CEO of Celltech Group in the UK until UCB acquired the company. G\u00f6ran is a qualified medical doctor and a founding fellow of the American College of Rheumatology. He was awarded an honorary doctors degree by Karolinska Institute in 2002.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

Vetenskapliga r\u00e5det V\u00e5rt vetenskapliga r\u00e5d best\u00e5r av ledande professorer, l\u00e4kare, forskare och experter inom olika medicinska omr\u00e5den. Ledam\u00f6terna har i sin tur ett gediget n\u00e4tverk inom sina respektive delsektorer. Totalt ing\u00e5r hundratals forskare och experter p\u00e5 vetenskapliga institutioner runt om i v\u00e4rlden. Detta ger f\u00f6rvaltarna m\u00f6jlighet till djupare insikter, samt tillg\u00e5ng till den senaste forskningen.  […]<\/p>\n","protected":false},"author":9,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-24488","page","type-page","status-publish","hentry"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/pages\/24488","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/comments?post=24488"}],"version-history":[{"count":149,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/pages\/24488\/revisions"}],"predecessor-version":[{"id":32338,"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/pages\/24488\/revisions\/32338"}],"wp:attachment":[{"href":"https:\/\/rhepa.se\/en\/wp-json\/wp\/v2\/media?parent=24488"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}